ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Sutantatug Envedotin

Also written as “SYS6002” and “CRB-701”.

Its studies are mostly in Oropharyngeal Neoplasms · Carcinoma, Transitional Cell · Uterine Cervical Neoplasms · Squamous Cell Carcinoma of Head and Neck, led by 2 companies.

Drug pageSutantatug Envedotin: every studyAll 6 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 13, 20256 company-led studies, 6 open or runningNext primary completion: Jan 16, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSPC Pharmaceutical Groupits history only44 open or runningphase 3since Nov 13, 2025Apr 25, 2025Dec 30, 2027phase 2 · NCT06989671
Corbus Pharmaceuticals22 open or runningphase 3since Aug 12, 2026Feb 8, 2024Jan 16, 2027phase 2 · NCT06265727

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Corbus Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Feb 8, 2024First study: phase 2 study in Solid Tumor, AdultFirst studyNCT06265727 · 348 planned · United States, France, Italy and more
  2. Jan 29, 2026Named sutantatug envedotinINNProposed as its International Nonproprietary Name in WHO's List 134 · before, SYS6002, CRB-701
  3. Aug 12, 2026Phase 3 study in Oropharyngeal NeoplasmsPhase 3 reachedNCT07768189 · 260 planned · United States, Austria, Belgium and more

Ahead

  1. Jan 16, 2027Primary completion: phase 2 study in Solid Tumor, AdultNCT06265727
  2. Dec 2027Primary completion: phase 3 study in Oropharyngeal NeoplasmsNCT07768189

TargetBeta

NECTIN4 →read by rule
“An antibody-drug conjugate (ADC) composed of sutantatug, an immunoglobulin G1 (IgG1) monoclonal antibody directed against the cell surface adhesion molecule and tumor-associated antigen (TAA) nectin-4 (PVRL4), site-specifically ”NCIt, by rule

Other programs on NECTIN4

ProgramCompanyFurthest phaseStudies
enfortumab vedotinruleAstellas Pharmaphase 420
notiretatug rezetecanJiangsu HengRui Medicinephase 314
bulumtatug fuvedotinruleMabwell (Shanghai) Biosciencephase 313
zelenectide pevedotinrulebicycletx-limitedphase 25
Anti-nectin-4 Antibody-drug Conjugate MK-3120ruleMerckphase 25
Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103ruleavenzo-therapeutics-incphase 21
Anti-nectin-4 Antibody-drug Conjugate IPH4502ruleinnate-pharmaphase 11
Anti-nectin-4/CD28 Bispecific Antibody RNDO-564rulerondo-therapeuticsphase 11
CT-202rulecontext-therapeutics-incphase 11

Studies

All 2 Corbus Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07768189Oropharyngeal Neoplasms · United States, Austria, Belgium and more3RecruitingDec 2027260
NCT06265727Solid Tumor, Adult · United States, France, Italy and more2RecruitingJan 16, 2027348

How it is read

Names in the registry

  • “SYS6002”, 4 entries
  • “CRB-701”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.